Applied DNA Sciences and Institute of Hematology to Present Revolutionary CAR T-cell Therapy Study

Applied DNA Sciences, Inc. (NASDAQ: APDN) and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) announced their upcoming presentation at the European Hematology Association 2024 Hybrid Congress. The presentation, based in Madrid from June 13 - 16, 2024, will focus on a pivotal study involving a non-viral approach for creating CAR T-cell therapies, particularly targeting refractory acute myeloid leukemia (AML).

This innovative study utilizes Applied DNA's Linea™ DNA in a fully enzymatic production process to develop CD123-specific CAR T-cells. This approach eliminates the use of viral vectors, potentially reducing production costs and enhancing manufacturing speed. The successful abstract, titled "Linear DNA Platform For The Non-Viral Point-Of-Care Production Of Car-T Cells" (Abstract Number: P1722), will detail these findings, and is set to significantly impact the field of gene therapeutics aimed at treating severe cancer forms.

The enzyme-driven method not only promises substantial yields but also avoids risks associated with antibiotic-resistance gene transfer. ÚHKT is seeking regulatory approval to commence clinical trials, which could pave the way for broader application of this technology in clinical settings. Presentation details by Dr. Pavel Otáhal will be available on the Congress' website starting May 14, 2024.